Papp KA, Lebwohl MG, Puig L, Ohtsuki M, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol 2021 Jun 22. doi: 10.1111/bjd.20595.
PMID: 34157132